Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma - A southwest oncology group study

David S. Alberts, Nancy Mason-Liddil, Stephanie J. Green, John D. Cowan, William S. Fletcher, Barbara Neilan, Jerry T. Guy, Robert B. Epstein

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Patients with a pathologically proven diagnosis of malignant melanoma were entered into a phase II trial of bisantrene. Eligibility criteria included: measurable, metastatic disease; performance status 0-2 SWOG; and adriamycin total cumulative dose of < 400 mg/m2. The initial bisantrene dosing schedule was 260 mg/m2 every three weeks for good risk patients. Due to the absence of an objective response and the lack of severe toxicity in the first 25 bisantrene treated patients, the starting dose was increased to 300 mg/m2 for good risk patients. Fifty-one patients received a median of two bisantrene courses (range 1-11 courses). Leukopenia was the major toxicity. Fifteen (68%) of the 22 good risk, intermediate dose patients (260 mg/m2), and 8 (80%) of the 10 good risk, high dose patients (300 mg/m2) evaluable for toxicity experienced mild-severe leukopenia. None of the 51 patients experienced a complete or partial response to bisantrene. Median survival was 3.3 months. We conclude that bisantrene is ineffective in the treatment of metastatic melanoma.

Original languageEnglish (US)
Pages (from-to)289-292
Number of pages4
JournalInvestigational New Drugs
Volume5
Issue number3
DOIs
StatePublished - Sep 1 1987

Keywords

  • bisantrene
  • melanomas
  • phase II

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma - A southwest oncology group study'. Together they form a unique fingerprint.

  • Cite this

    Alberts, D. S., Mason-Liddil, N., Green, S. J., Cowan, J. D., Fletcher, W. S., Neilan, B., Guy, J. T., & Epstein, R. B. (1987). Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma - A southwest oncology group study. Investigational New Drugs, 5(3), 289-292. https://doi.org/10.1007/BF00175300